Clarius Group LLC’s Denali Therapeutics DNLI Stock Holding History

Clarius Group LLC’s Portfolio DNLI Stock Details DNLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$6.09M	Buy	368,995 +9,250	+3%	+$156K	0.35%	37
2025 Q3	$5.22M	Sell	359,745 -9,250	-3%	-$133K	0.31%	40
2025 Q2	$5.16M	Hold	368,995	–	–	0.3%	40
2025 Q1	$5.02M	Sell	368,995 -41,000	-10%	-$786K	0.32%	40
2024 Q4	$8.36M	Hold	409,995	–	–	0.57%	28
2024 Q3	$11.9M	Hold	409,995	–	–	0.84%	19
2024 Q2	$9.52M	Buy	409,995 +17,777	+5%	+$341K	0.67%	22
2024 Q1	$8.05M	Buy	392,218 +13,956	+4%	+$262K	0.56%	27
2023 Q4	$8.12M	Hold	378,262	–	–	0.67%	26
2023 Q3	$7.8M	Sell	378,262 -5	-0%	-$127	0.74%	24
2023 Q2	$11.2M	Buy	378,267 +87,937	+30%	+$2.47M	0.86%	18
2023 Q1	$6.69M	Buy	290,330 +29,726	+11%	+$818K	0.57%	25
2022 Q4	$7.25M	Hold	260,604	–	–	0.65%	24
2022 Q3	$8M	Buy	260,604 +232,085	+814%	+$7.55M	0.8%	20
2022 Q2	$839K	Buy	28,519 +2,074	+8%	+$54.3K	0.08%	145
2022 Q1	$1.18M	Hold	26,445	–	–	0.09%	118
2021 Q4	$1.18M	Buy	26,445 +13,750	+108%	+$651K	0.09%	118
2021 Q3	$640K	Buy	12,695 +8,562	+207%	+$483K	0.06%	179
2021 Q2	$324K	Buy	+4,133	New	+$256K	0.03%	299

Other funds holding DNLI

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Clarius Group LLC's DNLI Position: Q4 2025 in Review

Clarius Group LLC increased its Denali Therapeutics (DNLI) stake by 2.6% in Q4 2025, buying an estimated $156K and bringing the position to 368,995 shares worth $6.09M. The position accounts for 0.35% of the portfolio, ranked #37.

Clarius Group LLC first reported a position in DNLI in Q2 2021 and has held it in 19 quarters since. The position peaked at $11.9M in Q3 2024. 250 funds tracked by Wall St. Rank hold DNLI as of Q4 2025.

Clarius Group LLC held 368,995 shares of Denali Therapeutics worth $6.09M as of Q4 2025.
Clarius Group LLC bought 9,250 Denali Therapeutics shares in Q4 2025, an estimated $156K.
Denali Therapeutics made up 0.35% of Clarius Group LLC's portfolio in Q4 2025, its #37 holding.
Clarius Group LLC first reported a position in Denali Therapeutics in Q2 2021 and has held it in 19 quarters since.
Clarius Group LLC's Denali Therapeutics position peaked at $11.9M in Q3 2024.
250 funds tracked by Wall St. Rank held Denali Therapeutics as of Q4 2025.

Based on Clarius Group LLC's 13F filing for Q4 2025, filed 14 Jan 2026.